Department of Neurology, the First Affiliated Hospital of Chongqing Medical University, No.1 Youyi Road, Yuzhong District, Chongqing 400016, China.
Department of Neurology, the First Affiliated Hospital of Chongqing Medical University, No.1 Youyi Road, Yuzhong District, Chongqing 400016, China; Chongqing Key Laboratory of Neurobiology, Chongqing, China.
Clin Biochem. 2024 Mar;125:110733. doi: 10.1016/j.clinbiochem.2024.110733. Epub 2024 Feb 17.
Recently acquired data suggests that sodium-glucose cotransporter-2 (SGLT2) may be a therapeutic target for cerebral ischemia. The specific impact of SGLT2 in acute ischemic stroke (AIS) remains unknown. We aimed to explore the levels of SGLT2 in AIS patients and its association with functional prognosis.
In this study, 132 AIS patients and 44 healthy controls were recruited prospectively to determine serum SGLT2 levels. Logistic regression analysis was employed to assess the association between serum SGLT2 level and stroke risk as well as 3-month outcome. Receiver operating characteristic (ROC) curves were utilized to evaluate predictive values for blood biomarkers.
Serum SGLT2 levels were significantly higher (P =.000) in AIS patients (47.1 (interquartile range [IQR]: 42.4-50.9) ng/mL) than healthy controls (35.7 (IQR: 28.6-39.5) ng/mL). The optimal SGLT2 cutoff point for diagnosing AIS was 39.55 ng/mL, with a sensitivity of 90.2 % and specificity of 77.3 %. Serum levels of SGLT2 were negatively correlated with the onset time of AIS (linear fit R = 0.056, P =.006), but were not associated with National Institutes of Health Stroke Scale (NIHSS) scores (r = 0.007, P >.05) and lesion volume (r = -0.151, P >.05). SGLT2 was not remarkably different between patients with unfavorable and favorable outcomes (46.7 (IQR: 41.9-49.6) ng/mL vs 47.6 (IQR: 42.5-51.9) ng/mL; P =.321).
The serum SGLT2 concentration may be a potential biomarker for the diagnosis of AIS. However, it does not exhibit any association with disease severity or functional prognosis.
最近获得的数据表明，钠-葡萄糖共转运蛋白 2（SGLT2）可能是治疗脑缺血的靶点。SGLT2 在急性缺血性脑卒中（AIS）中的具体作用尚不清楚。我们旨在探讨 AIS 患者 SGLT2 的水平及其与功能预后的关系。
本研究前瞻性纳入 132 例 AIS 患者和 44 名健康对照者，以确定血清 SGLT2 水平。采用 Logistic 回归分析评估血清 SGLT2 水平与卒中风险及 3 个月结局的关系。受试者工作特征（ROC）曲线用于评估生物标志物的预测价值。
AIS 患者血清 SGLT2 水平显著升高（P = 0.000）[47.1（四分位距[IQR]：42.4-50.9）ng/ml]，显著高于健康对照组[35.7（IQR：28.6-39.5）ng/ml]。诊断 AIS 的最佳 SGLT2 截断点为 39.55ng/ml，其敏感性为 90.2%，特异性为 77.3%。血清 SGLT2 水平与 AIS 发病时间呈负相关（线性拟合 R=0.056，P=0.006），但与美国国立卫生研究院卒中量表（NIHSS）评分（r=0.007，P>.05）和病灶体积（r=-0.151，P>.05）无关。预后不良和预后良好的患者 SGLT2 水平差异无统计学意义[46.7（IQR：41.9-49.6）ng/ml 比 47.6（IQR：42.5-51.9）ng/ml；P=0.321]。
血清 SGLT2 浓度可能是 AIS 的潜在诊断生物标志物。然而，它与疾病严重程度或功能预后均无关联。
